Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2025)
Xencor (XNCR) reported Asset Writedowns and Impairment of -$8.3 million for Q4 2025, down 629.58% quarter-over-quarter from $1.6 million in Q3 2025.
Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2025) Analysis & Trends
Xencor (XNCR) has 13 years of Asset Writedowns and Impairment data on file, last reported at -$8.3 million in Q4 2025.
- Asset Writedowns and Impairment for Q4 2025 came in at -$8.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.9 million (down 204.74% YoY), and the FY2024 annual result was $20.4 million, up 1512.47% from the prior year.
- Asset Writedowns and Impairment retreated to -$8.3 million in Q4 2025 per XNCR's latest filing, from $1.6 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $20.6 million in Q1 2024 and troughed at -$8.3 million in Q4 2025.
- A 5-year average of $1.4 million and a median of $300000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 6333.02% in 2024 and fell as far as 173.33% in 2024.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $207000.0 in 2021, then slipped by 13.53% to $179000.0 in 2022, then soared by 162.57% to $470000.0 in 2023, then tumbled by 146.81% to -$220000.0 in 2024, then slumped by 3667.27% to -$8.3 million in 2025.
- Business Quant data shows XNCR's Asset Writedowns and Impairment at -$8.3 million in Q4 2025, $1.6 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.29 Mn |
| Dec 31, 2025 | -8.29 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Jun 30, 2024 | -220,000.00 |
| Jun 30, 2024 | -220,000.00 |
| Mar 31, 2024 | 20.65 Mn |
| Mar 31, 2024 | 20.65 Mn |
| Dec 31, 2023 | 470,000.00 |
| Dec 31, 2023 | 470,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 321,000.00 |
| Mar 31, 2023 | 321,000.00 |